CA-MAWI-DNA-TECHNOLOGIES
10.5.2022 15:02:14 CEST | Business Wire | Press release
Mawi DNA Technologies (Mawi), a medical device company focusing on the development of innovative technologies for biosampling, has launched the NextSWAB™, a 100% medical-grade plastic swab designed and manufactured in the US. Mawi launched this new product in response to the COVID-19 swab shortage. It is designed for high efficiency collection without the possibility of contamination from glue or fibers used in flock and cotton swabs that may inhibit PCR based assays. NextSWAB™ is currently optimized for nasal sample collection with validation for other sample types ongoing.
“The NextSWAB™ sterile sampling applicator is six inches in length with a unique head design positioned at the distal end,” said Dr. Bassam El-Fahmawi, CEO of Mawi. “The swab head has two channels separated by a septum that retains the collected nasal material which can then be released into the transport media with a gentle shake. The flexible head fits into crevices with ease and effectiveness. It enables anterior nasal sample collection with minimal user discomfort sufficient for a meaningful result,” Dr. El-Fahmawi added.
The NextSWAB™ is compatible with many sample transport tubes making it ideal for multiple swab sample pooling in a single tube. However, to achieve optimal results, it is most effective when used in conjunction with Mawi’s iSWAB-Microbiome-EL sample collection technology which allows users to skip the RNA extraction step in COVID-19 molecular tests. A second nasal sample can be added to the same tube creating a more concentrated sample to improve overall reliability of the test. The NextSWAB™ comes ready for use and does not require any preparation for specimen collection.
“Our NextSWAB™ fully releases its contents into the sample transport media removing the need for the swab to be transported with the sample,” Dr. El-Fahmawi pointed out. “A fully concentrated liquid sample can then be quickly processed with robotic liquid handling systems or any laboratory workflow. During initial R&D testing, the unique and patent pending head design has shown higher collection efficiency for nasal (mid-turbinate and anterior nares) samples than flocked swabs,” he said.
With demand for COVID-19 sample collection swabs, the supply chain line for the NextSWAB™ is reliable and stable thanks to the plastic molded construction and USA based manufacturing. For more information on the NextSWAB™, visit www.mawidna.com .
About Mawi DNA Technologies
Mawi DNA Technologies, founded in 2013, has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Mawi’s mission is to uphold sample integrity from anywhere in the world at room temperature, enabling true sample diversity across any geography or population segment. At Mawi, The Future of Biosampling is Here™. For more information, visit http://www.mawidna.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005587/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
InvestEco Sustainable Food Fund IV Holds a Final Close With Total Commitments of C$106M29.6.2026 15:00:00 CEST | Press release
InvestEco Capital is pleased to announce the final close of the InvestEco Sustainable Food Fund IV. This fund will continue InvestEco’s work of investing in high-growth food companies that promote health and sustainability in the food sector. The Fund closed with total commitments of C$106M, the largest InvestEco fund to date. Investors include Farm Credit Canada, Export Development Canada, Business Development Bank of Canada, Fonds de solidarité FTQ, and two Government of Canada Social Finance Fund wholesalers: Boann and Realize Capital Partners. In addition, the Fund received commitments from a number of private investors and family offices. The Fund's investments to date include Humble Snacks, Little Sesame, Mid-Day Squares and Algae Cooking Club. The Fund expects to make a further 6 - 10 investments over the next few years. InvestEco Capital, founded in 2002, is a Toronto-based venture capital firm and impact investor focused on the sustainable food sector. For more information, em
Geoswift and SKUx Announce Strategic Partnership to Develop a First-of-Its-Kind Programmable Stablecoin Commerce Network29.6.2026 14:00:00 CEST | Press release
Bridging digital assets, traditional finance, enterprise treasury, and agentic commerce through global programmable money infrastructure Geoswift and SKUx announced a groundbreaking partnership to develop a next-generation programmable stablecoin commerce network. This strategic collaboration bridges digital assets, traditional finance, and real-world commerce at a global scale, representing a "one-of-one" opportunity by combining Geoswift's global infrastructure with SKUx's specialized item-level controls directly within point-of-sale (POS) systems. While enterprise stablecoin usage continues to accelerate globally, governments, enterprises, payment networks, and AI-driven commerce platforms are increasingly seeking programmable payment infrastructure that can bridge digital assets with real-world commerce. The innovation goes far beyond treasury management or even enabling consumers to spend stablecoins at retail locations. Instead, it unlocks true "programmable money" with embedded
Esri Sponsors Smithsonian Exhibition Showcasing Natural and Cultural Objects from All 50 States29.6.2026 14:00:00 CEST | Press release
From These Lands Exhibition Highlights Connections Between People, Place, and Natural World Through Physical Specimens and Digital Maps Esri is the lead sponsor of the Smithsonian's From These Lands exhibition and developed maps powered by ArcGIS and a digital companion to extend engagement beyond the museum. The exhibition features more than 600 specimens and cultural artifacts from all 50 states, Washington, DC, and US territories, drawn from the Smithsonian's National Museum of Natural History's collection of over 148 million objects. Designed around themes of connection, diversity, and discovery, the exhibit explores how landscapes, ecosystems, and cultural traditions shape one another across regions and time. Animated mapping experiences enable visitors to explore topography, biomes, geology, migration patterns, and watersheds, revealing relationships across the continent. ArcGIS StoryMaps transforms the physical exhibit into an accessible digital narrative, extending its reach to
Cartilage Tissue Engineering Heads to Orbit in NSF and NASA-supported Study at the International Space Station29.6.2026 14:00:00 CEST | Press release
UC Irvine researchers use single cell RNA sequencing to study cartilage tissue engineered in microgravity Researchers in the DELTAi Lab at the University of California, Irvine, working with NASA, are using Evercode Cell Fixation to preserve samples aboard the International Space Station as part of a study of cartilage tissue engineering in microgravity. The unprecedented work, part of a National Science Foundation (NSF)-funded grant led by Dr. Wendy Brown and Dr. Kyriacos Athanasiou, announced today by Parse Biosciences, aims to advance treatments for the hundreds of millions of people worldwide affected by cartilage injury. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629548658/en/ Rachel Nordberg, PhD, from the DELTAi Lab at UC Irvine, prepping the BioServe device before it goes into orbit. Cartilage injuries cause significant pain and disability, and the need for implants that can repair or regenerate damaged tissue
Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour29.6.2026 13:55:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen," SSE: 688796; HKEX: 02315) today announced that it has received a first-instance civil judgment from the Shanghai Intellectual Property Court. The court ruled that Biocytogen did not infringe the relevant patent rights asserted by the plaintiff, Harbour Antibodies BV ("Harbour"), and ordered the plaintiff to bear the litigation costs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629347368/en/ Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour The judgment marks a significant first-instance outcome in the litigation and further affirms the independent innovation and intellectual property compliance of Biocytogen's core technology platforms. It also provides greater clarity for existing and prospective partners evaluating the RenNano® platform, reinforcing confidence in the Company's technology platforms and long-term innovation capabi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom